LDL-cholesterol lowering medication linked to lower mortality in high-risk patients
Mass General Brigham Heart and Vascular Institute researchers have found that high-risk patients who had not previously experienced a heart attack or stroke had a lower risk of death after taking the cholesterol-lowering drug evolocumab (on top of standard cholesterol-lowering therapy) as part of a
<p>Mass General Brigham Heart and Vascular Institute researchers have found that high-risk patients who had not previously experienced a heart attack or stroke had a lower risk of death after taking the cholesterol-lowering drug evolocumab (on top of standard cholesterol-lowering therapy) as part of a </p>